Skip to main content

2 Result(s)

within I. P. Barton Remove this filter

and

  1. Article

    Open Access

    Effects of risedronate on fracture risk in postmenopausal women with osteopenia

    This posthoc analysis of four trials studied the efficacy of risedronate to reduce fragility fractures in postmenopausal women with osteopenia (i.e., T-scores between −1 and −2.5). Risedronate reduced the frac...

    E. S. Siris, J. A. Simon, I. P. Barton, M. R. McClung… in Osteoporosis International (2008)

    Download PDF (130 KB) View Article

  2. No Access

    Article

    Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

    The aim of this study was to examine the effects of risedronate (5 mg/daily) in patients identified solely on the basis of a prior fragility fracture, without BMD as an inclusion criterion. A total of 1,802 pa...

    J. A. Kanis, I. P. Barton, O. Johnell in Osteoporosis International (2005)